Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STILD: Low-dose vs standard-dose SMX/TMP prophylaxis for Pneumocystis pneumonia in interstitial lung disease
jRCT1011250066Recruiting
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of trimethoprim + sulfamethoxazole in pneumocystis pneumonia (PCP) (2 arms). Primary endpoint: Primary: Discontinuation due to adverse events and incidence of grade ≥3 adverse events. Started Jul 2025; status: recruiting.
02
Drugs
trimethoprim + sulfamethoxazole
03
Conditions
pneumocystis pneumonia (PCP)
Beyond the preview
Go deeper on jRCT1011250066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1011250066.